These findings support the use of DHA as a candidate therapeutic agent for minimizing HER2-mediated oncogenesis in breast cancer cells by disturbing a PPARγ-independent lipogenic phenotype associated with HER2 overexpression. This evidence concerns the gene ERBB2 and breast carcinoma.